To improve clinical guidance in the therapy of diseases, official treatment recommendations are provided in Switzerland. These are comparable to medical guidelines in Germany.
In 2016, the treatment recommendations for the acute treatment of depressive episodes were revised by the Swiss Society for Anxiety & Depression (SGAD) and the Swiss Society for Biological Psychiatry (SGBP) in collaboration with the Swiss Society for Psychiatry and Psychotherapy (SGPP). In the course of this revision, the ABCB1 test was included in the treatment recommendations and is advised for the treatment of a patient with antidepressants.
The ABCB1 test is a moleculargenetic test that detects polymorphisms in the ABCB1 gene. These genetic variants influence the transport of certain antidepressants in the blood-brain-barrier and thus their intracerebral concentration and efficacy. The ABCB1 test delivers a decision aid for physicians with respect to the type and dosing of antidepressant medication, leading to faster remission time and higher overall remission rates.
For more information visit www.abcb1-test.de